CorriXR Therapeutics
PrivateLast Round
Series A
Aug 19, 2025
Total Funding Raised
$11.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
CorriXR Therapeutics is a biotechnology company that develops genetic medicines using a CRISPR-based gene editing platform to treat drug-resistant solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CorriXR Therapeutics Comparables
Compare CorriXR Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ArsenalBio | 68% | |
| Tune Therapeutics | 63% | |
| Intellia Therapeutics | 63% |
CorriXR Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 19, 2025 | ||||
| Seed | Jan 22, 2024 | ||||
| Seed | Oct 11, 2022 |
Key People
Founding team and executive leadership
CorriXR Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Delaware Division of Small Business | Series A |
| Cortado Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 60% MoM.
- Jan 9, 2026
Developing an inhaler device for cancer treatment delivery.
Recent news
Latest coverage and updates
- hiresJul 17, 2026
CorriXR Therapeutics, Inc. hired Nancy as Chair of the Board of Directors on Jul 17th '26.
CorriXR Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about CorriXR Therapeutics's valuation, stock price, and market status.
Is CorriXR Therapeutics a public or private company?
CorriXR Therapeutics is a private company.
What is the current stock price of CorriXR Therapeutics?
CorriXR Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is CorriXR Therapeutics worth (valuation)?
Valuation information for CorriXR Therapeutics is not publicly available.
Can I buy CorriXR Therapeutics stock?
CorriXR Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was CorriXR Therapeutics's last funding round?
CorriXR Therapeutics's most recent funding round was Series A on August 19, 2025.
Who are the main investors in CorriXR Therapeutics?
Key investors in CorriXR Therapeutics include Cortado Ventures.
Will CorriXR Therapeutics IPO soon?
No public IPO plans have been announced for CorriXR Therapeutics.
How can I track CorriXR Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CorriXR Therapeutics's secondary market activity and sign up for updates.